Abstract 2505
Background
Worldwide, according to WHO 2014, over 19 million patients are in need of palliative care, 34% of them will die of cancer. Palliative care research brings many challenges. This metaresearch study aims to evaluate how clinical research on palliative care is conducted within the setting of incurable cancer.
Methods
Clinicaltrials.gov was searched to identify all registered studies investigating palliative care in patients with advanced or metastatic cancer. The EORTC QLQ-C15-PAL questionnaire was used to define the domains of interest. We excluded studies investigating cancer-directed therapy, management of cancer treatment-related adverse events, and diagnostic tests. Publication status was crosschecked using PubMed.
Results
Of 3950 identified studies, 514 studies were included. The most frequent reason for exclusion was cancer-directed therapy (2491). In 2007-2012, 161 studies were registered vs 245 in 2013-2018. Included studies were interventional (84%, 430/514) or observational (16%, 84/514). Most studies were sponsored by academia (79%), and conducted in North America (57%) or Europe (25%). 67% of studies evaluated a heterogeneous population (any tumour type). 60% were monocentric studies. Interventional studies most frequently investigated systemic drugs (34%, 148/430), behavioural interventions (29%, 125/430), and procedures for pain (24%, 103/430). Pain, quality of life and physical function were the most studied palliative issues (188, 95, 52 studies respectively). Fewer studies investigated health care planning (45), emotional function (35), appetite (22), social function (22), fatigue (20), dyspnea (18), sleep disturbance (5), cognitive function (5), nausea (4), and constipation (3). The most applied primary outcome measures were efficacy/symptom control (61.5%, 316), quality of life (14.2%, 73) and feasibility (11.7%, 60). Only 16% of the closed studies had published results.
Conclusions
The studies investigating palliative care in patients with incurable tumours constitute a very small part of cancer clinical research. More than one third of studies examine pain, leaving other palliative issues less explored in clinical research. Furthermore, the results of these studies are under reported in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract